Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. 2012

Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
Department of Internal Medicine, National Hospital Organization Toneyama National Hospital, Toyonaka, Japan. mikisuke@toneyama.go.jp

BACKGROUND Pulmonary cachexia is common in advanced chronic obstructive pulmonary disease (COPD), culminating in exercise intolerance and a poor prognosis. Ghrelin is a novel growth hormone (GH)-releasing peptide with GH-independent effects. The efficacy and safety of adding ghrelin to pulmonary rehabilitation (PR) in cachectic COPD patients were investigated. RESULTS In a multicenter, randomized, double-blind, placebo-controlled trial, 33 cachectic COPD patients were randomly assigned PR with intravenous ghrelin (2 µg/kg) or placebo twice daily for 3 weeks in hospital. The primary outcomes were changes in 6-min walk distance (6-MWD) and the St. George Respiratory Questionnaire (SGRQ) score. Secondary outcomes included changes in the Medical Research Council (MRC) scale, and respiratory muscle strength. At pre-treatment, serum GH levels were increased from baseline levels by a single dose of ghrelin (mean change, +46.5 ng/ml; between-group p<0.0001), the effect of which continued during the 3-week treatment. In the ghrelin group, the mean change from pre-treatment in 6-MWD was improved at Week 3 (+40 m, within-group p = 0.033) and was maintained at Week 7 (+47 m, within-group p = 0.017), although the difference between ghrelin and placebo was not significant. At Week 7, the mean changes in SGRQ symptoms (between-group p = 0.026), in MRC (between-group p = 0.030), and in maximal expiratory pressure (MEP; between-group p = 0.015) were better in the ghrelin group than in the placebo group. Additionally, repeated-measures analysis of variance (ANOVA) indicated significant time course effects of ghrelin versus placebo in SGRQ symptoms (p = 0.049) and MEP (p = 0.021). Ghrelin treatment was well tolerated. CONCLUSIONS In cachectic COPD patients, with the safety profile, ghrelin administration provided improvements in symptoms and respiratory strength, despite the lack of a significant between-group difference in 6-MWD. BACKGROUND UMIN Clinical Trial Registry C000000061.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D011795 Surveys and Questionnaires Collections of data obtained from voluntary subjects. The information usually takes the form of answers to questions, or suggestions. Community Survey,Nonrespondent,Questionnaire,Questionnaires,Respondent,Survey,Survey Method,Survey Methods,Surveys,Baseline Survey,Community Surveys,Methodology, Survey,Nonrespondents,Questionnaire Design,Randomized Response Technique,Repeated Rounds of Survey,Respondents,Survey Methodology,Baseline Surveys,Design, Questionnaire,Designs, Questionnaire,Methods, Survey,Questionnaire Designs,Questionnaires and Surveys,Randomized Response Techniques,Response Technique, Randomized,Response Techniques, Randomized,Survey, Baseline,Survey, Community,Surveys, Baseline,Surveys, Community,Techniques, Randomized Response
D012129 Respiratory Function Tests Measurement of the various processes involved in the act of respiration: inspiration, expiration, oxygen and carbon dioxide exchange, lung volume and compliance, etc. Lung Function Tests,Pulmonary Function Tests,Function Test, Pulmonary,Function Tests, Pulmonary,Pulmonary Function Test,Test, Pulmonary Function,Tests, Pulmonary Function,Function Test, Lung,Function Test, Respiratory,Function Tests, Lung,Function Tests, Respiratory,Lung Function Test,Respiratory Function Test,Test, Lung Function,Test, Respiratory Function,Tests, Lung Function,Tests, Respiratory Function
D002100 Cachexia General ill health, malnutrition, and weight loss, usually associated with chronic disease.
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
January 2015, PloS one,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
October 2019, American journal of respiratory and critical care medicine,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
January 2016, Pharmacology,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
May 2001, Lancet (London, England),
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
July 1996, The European respiratory journal,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
September 2006, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
February 2006, European journal of clinical nutrition,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
January 2022, Pulmonary circulation,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
April 2014, The Lancet. Respiratory medicine,
Keisuke Miki, and Ryoji Maekura, and Noritoshi Nagaya, and Masamitsu Nakazato, and Hiroshi Kimura, and Shinsuke Murakami, and Shunsuke Ohnishi, and Toru Hiraga, and Mari Miki, and Seigo Kitada, and Kenji Yoshimura, and Yoshitaka Tateishi, and Yasuji Arimura, and Nobuhiro Matsumoto, and Masanori Yoshikawa, and Kenichi Yamahara, and Kenji Kangawa
August 2020, American journal of respiratory and critical care medicine,
Copied contents to your clipboard!